The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Tanderil     4-butyl-1-(4-hydroxyphenyl)- 2-phenyl...

Synonyms: Aradinum, Butanora, Butanova, Butilene, Crovaril, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of oxyphenbutazone


Psychiatry related information on oxyphenbutazone


High impact information on oxyphenbutazone


Chemical compound and disease context of oxyphenbutazone


Biological context of oxyphenbutazone


Anatomical context of oxyphenbutazone


Associations of oxyphenbutazone with other chemical compounds


Gene context of oxyphenbutazone

  • CONCLUSION: Optimal sensitivity for HNE ANCA requires multimodality testing [34].
  • Cyclosporine A was a potent competitive inhibitor of CQA metabolism, providing initial evidence that formation of metabolite I was catalyzed by proteins of the CYP3 gene family [35].
  • STUDY DESIGN: Optimal folding of the chemokine molecule is thought to be important for its biologic activity [36].
  • In competition binding studies, various CTs and their analogues demonstrated a similar rank order of potency to that seen in other CT receptor systems, Optimal binding occurred in the pH range 6.5-7.5, and was decreased in the presence of NaCl concentrations greater than 200 mM [37].
  • Frontline: Optimal T cell activation requires the engagement of CD6 and CD166 [38].

Analytical, diagnostic and therapeutic context of oxyphenbutazone


  1. A computer-assisted management program for antibiotics and other antiinfective agents. Evans, R.S., Pestotnik, S.L., Classen, D.C., Clemmer, T.P., Weaver, L.K., Orme, J.F., Lloyd, J.F., Burke, J.P. N. Engl. J. Med. (1998) [Pubmed]
  2. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. Agnelli, G., Prandoni, P., Santamaria, M.G., Bagatella, P., Iorio, A., Bazzan, M., Moia, M., Guazzaloca, G., Bertoldi, A., Tomasi, C., Scannapieco, G., Ageno, W. N. Engl. J. Med. (2001) [Pubmed]
  3. Antithyroid drug therapy for Graves' disease during pregnancy. Optimal regimen for fetal thyroid status. Momotani, N., Noh, J., Oyanagi, H., Ishikawa, N., Ito, K. N. Engl. J. Med. (1986) [Pubmed]
  4. Oxyphenbutazone-induced sialadenitis. Chen, J.H., Ottolenghi, P., Distenfeld, A. JAMA (1977) [Pubmed]
  5. J-curve not burned off by HOT study. Hypertension Optimal Treatment. Kaplan, N. Lancet (1998) [Pubmed]
  6. DSM-IV field trials for attention deficit hyperactivity disorder in children and adolescents. Lahey, B.B., Applegate, B., McBurnett, K., Biederman, J., Greenhill, L., Hynd, G.W., Barkley, R.A., Newcorn, J., Jensen, P., Richters, J. The American journal of psychiatry. (1994) [Pubmed]
  7. Risk management frameworks for human health and environmental risks. Jardine, C., Hrudey, S., Shortreed, J., Craig, L., Krewski, D., Furgal, C., McColl, S. Journal of toxicology and environmental health. Part B, Critical reviews. (2003) [Pubmed]
  8. Post-traumatic stress disorder among patients with chronic pain and chronic fatigue. Roy-Byrne, P., Smith, W.R., Goldberg, J., Afari, N., Buchwald, D. Psychological medicine. (2004) [Pubmed]
  9. Optimization of conditioning therapy for leukemia prior to BMT. I. Optimal synergism between cyclophosphamide and total body irradiation for eradication of murine B cell leukemia (BCL1). Loewenthal, E., Weiss, L., Samuel, S., Or, R., Slavin, S. Bone Marrow Transplant. (1993) [Pubmed]
  10. Cooperation between parents in caring for diabetic children: relations to metabolic control and parents' field-dependence-independence. Rydén, O., Johnsson, P., Nevander, L., Sjöblad, S., Westbom, L. Diabetes Res. Clin. Pract. (1993) [Pubmed]
  11. Redox Regulation Facilitates Optimal Peptide Selection by MHC Class I during Antigen Processing. Park, B., Lee, S., Kim, E., Cho, K., Riddell, S.R., Cho, S., Ahn, K. Cell (2006) [Pubmed]
  12. In vitro growth of imaginal disks from Drosophila melanogaster. Davis, K.T., Shearn, A. Science (1977) [Pubmed]
  13. What clinicians should know about the QT interval. Al-Khatib, S.M., LaPointe, N.M., Kramer, J.M., Califf, R.M. JAMA (2003) [Pubmed]
  14. New method of delivering gene-altered Kupffer cells to rat liver: studies in an ischemia-reperfusion model. Froh, M., Wheeler, M.D., Smutney, O., Zhong, Z., Bradford, B.U., Thurman, R.G. Gastroenterology (2003) [Pubmed]
  15. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Dickstein, K., Kjekshus, J. Lancet (2002) [Pubmed]
  16. Dobutamine echocardiography in myocardial hibernation. Optimal dose and accuracy in predicting recovery of ventricular function after coronary angioplasty. Afridi, I., Kleiman, N.S., Raizner, A.E., Zoghbi, W.A. Circulation (1995) [Pubmed]
  17. Acute toxicity of pyrazolones. Okonek, S., Reinecke, H.J. Am. J. Med. (1983) [Pubmed]
  18. Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment. Kjeldsen, S.E., Kolloch, R.E., Leonetti, G., Mallion, J.M., Zanchetti, A., Elmfeldt, D., Warnold, I., Hansson, L. J. Hypertens. (2000) [Pubmed]
  19. Substituted thiosemicarbazides and corresponding cyclized 1,3,4-oxadiazoles and their anti-inflammatory activity. Raman, K., Singh, H.K., Salzman, S.K., Parmar, S.S. Journal of pharmaceutical sciences. (1993) [Pubmed]
  20. Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan. Dickstein, K., Kjekshus, J. Am. J. Cardiol. (1999) [Pubmed]
  21. Mesenchymal cells stimulate human intestinal intraepithelial lymphocytes. Roberts, A.I., Nadler, S.C., Ebert, E.C. Gastroenterology (1997) [Pubmed]
  22. The use of restriction fragment length polymorphisms in paternity analysis. Smouse, P.E., Chakraborty, R. Am. J. Hum. Genet. (1986) [Pubmed]
  23. Genetics of classic von Willebrand's disease. II. Optimal assignment of the heterozygous genotype (diagnosis) by discriminant analysis. Miller, C.H., Graham, J.B., Goldin, L.R., Elston, R.C. Blood (1979) [Pubmed]
  24. Dimerization of Laforin Is Required for Its Optimal Phosphatase Activity, Regulation of GSK3beta Phosphorylation, and Wnt Signaling. Liu, Y., Wang, Y., Wu, C., Liu, Y., Zheng, P. J. Biol. Chem. (2006) [Pubmed]
  25. Trypanosoma cruzi: induction of microbicidal activity in human mononuclear phagocytes. Nogueira, N., Chaplan, S., Reesink, M., Tydings, J., Cohn, Z.A. J. Immunol. (1982) [Pubmed]
  26. Pleiotropic activities of human interferons are mediated by multiple response pathways. Forti, R.L., Mitchell, W.M., Hubbard, W.C., Workman, R.J., Forbes, J.T. Proc. Natl. Acad. Sci. U.S.A. (1984) [Pubmed]
  27. The 3BP2 Adapter Protein Is Required for Optimal B-Cell Activation and Thymus-Independent Type 2 Humoral Response. Chen, G., Dimitriou, I.D., La Rose, J., Ilangumaran, S., Yeh, W.C., Doody, G., Turner, M., Gommerman, J., Rottapel, R. Mol. Cell. Biol. (2007) [Pubmed]
  28. Mitochondrial gene expression in saccharomyces cerevisiae. I. Optimal conditions for protein synthesis in isolated mitochondria. McKee, E.E., Poyton, R.O. J. Biol. Chem. (1984) [Pubmed]
  29. Effects of ipriflavone and its metabolites on a clonal osteoblastic cell line. Benvenuti, S., Tanini, A., Frediani, U., Bianchi, S., Masi, L., Casano, R., Bufalino, L., Serio, M., Brandi, M.L. J. Bone Miner. Res. (1991) [Pubmed]
  30. Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure. Luo, F.R., Yang, Z., Camuso, A., Smykla, R., McGlinchey, K., Fager, K., Flefleh, C., Castaneda, S., Inigo, I., Kan, D., Wen, M.L., Kramer, R., Blackwood-Chirchir, A., Lee, F.Y. Clin. Cancer Res. (2006) [Pubmed]
  31. Safety and efficacy of isoniazid chemoprophylaxis administered during liver transplant candidacy for the prevention of posttransplant tuberculosis. Singh, N., Wagener, M.M., Gayowski, T. Transplantation (2002) [Pubmed]
  32. Cytotoxic effects of cytokines on islet beta-cells: evidence for involvement of eicosanoids. Rabinovitch, A., Baquerizo, H., Sumoski, W. Endocrinology (1990) [Pubmed]
  33. Reversible restriction of vesicular stomatitis virus in permissive cells treated with inhibitors of prostaglandin biosynthesis. Mukherjee, P.K., Simpson, R.W. Virology (1984) [Pubmed]
  34. Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine-induced midline destructive lesions but not autoimmune vasculitis. Wiesner, O., Russell, K.A., Lee, A.S., Jenne, D.E., Trimarchi, M., Gregorini, G., Specks, U. Arthritis Rheum. (2004) [Pubmed]
  35. Characterization of the cytochrome P-450 gene family responsible for the N-dealkylation of the ergot alkaloid CQA 206-291 in humans. Ball, S.E., Maurer, G., Zollinger, M., Ladona, M., Vickers, A.E. Drug Metab. Dispos. (1992) [Pubmed]
  36. Antiviral chemokines: intracellular life of recombinant C-C chemokine RANTES. Owais, M., Arya, S.K. J. Hum. Virol. (1999) [Pubmed]
  37. Reversible calcitonin binding to solubilized sheep brain binding sites. Sexton, P.M., Schneider, H.G., D'Santos, C.S., Mendelsohn, F.A., Kemp, B.E., Moseley, J.M., Martin, T.J., Findlay, D.M. Biochem. J. (1991) [Pubmed]
  38. Frontline: Optimal T cell activation requires the engagement of CD6 and CD166. Hassan, N.J., Barclay, A.N., Brown, M.H. Eur. J. Immunol. (2004) [Pubmed]
  39. Coronary angiography after thrombolytic therapy for acute myocardial infarction. Topol, E.J., Holmes, D.R., Rogers, W.J. Ann. Intern. Med. (1991) [Pubmed]
  40. Coronary stenting after rotational atherectomy in calcified and complex lesions. Angiographic and clinical follow-up results. Moussa, I., Di Mario, C., Moses, J., Reimers, B., Di Francesco, L., Martini, G., Tobis, J., Colombo, A. Circulation (1997) [Pubmed]
  41. Final results of the Balloon vs Optimal Atherectomy Trial (BOAT). Baim, D.S., Cutlip, D.E., Sharma, S.K., Ho, K.K., Fortuna, R., Schreiber, T.L., Feldman, R.L., Shani, J., Senerchia, C., Zhang, Y., Lansky, A.J., Popma, J.J., Kuntz, R.E. Circulation (1998) [Pubmed]
  42. Oral anticoagulant therapy during and after coronary angioplasty the intensity and duration of anticoagulation are essential to reduce thrombotic complications. ten Berg, J.M., Hutten, B.A., Kelder, J.C., Verheugt, F.W., Plokker, H.W. Circulation (2001) [Pubmed]
  43. Platelet transfusion therapy. Optimal donor selection with a combination of lymphocytotoxicity and platelet fluorescence tests. Brand, A., van Leeuwen, A., Eernisse, J.G., van Rood, J.J. Blood (1978) [Pubmed]
WikiGenes - Universities